We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Novel Fluorescent Agent Helps Guide Removal of Ovarian Cancer Tumors

By MedImaging International staff writers
Posted on 21 Jun 2016
Print article
Image: OTL38 fluorescence imaging of mouse followed by EC17 fluorescence imaging, both with HeLa tumor burden (Photo courtesy of Purdue University).
Image: OTL38 fluorescence imaging of mouse followed by EC17 fluorescence imaging, both with HeLa tumor burden (Photo courtesy of Purdue University).
The results of a trial, published in the June 2016 issue of the journal Clinical Cancer Research indicate that a new tumor-specific fluorescent agent, together with an imaging system, can enable surgeons to remove 29% more malignant lesions than currently possible.

The researchers first enrolled 30 healthy volunteers to help them determine the optimum dosage and time window for the procedure, and then tested the fluorescent agent in 12 ovarian cancer patients. The researchers also measured tolerability and pharmacokinetics, and whether surgeons could use the procedure.

The new fluorescent agent OTL38, which binds to Folate Receptor-alpha (FRα), was developed by researchers from Purdue University (West Lafayette, IN, USA), and was used for the first time in human subjects by researchers at the Centre for Human Drug Research (Leiden, Netherlands). According to the researchers FRα is expressed in relatively low levels in normal human tissue, but is present in more than 90% of ovarian cancer tissue.

Author of the study, Alexander L. Vahrmeijer MD, PhD, Leiden University Medical Center (LUMC; Leiden Netherlands), said, "Surgery is the most important treatment for ovarian cancer, and surgeons mainly have to rely on their naked eyes to identify tumor tissue, which is not optimal. Near infrared (NIR) fluorescence imaging is a novel technique that may assist the surgeons to improve visualization of tumors during surgery. In our study, using a tumor-specific fluorescent agent and a dedicated imaging system, a fluorescent signal was detected in tumors in real time during a surgical procedure for ovarian cancer called cytoreduction. This allowed resection of additional tumor lesions that were not visible to the surgeons' naked eyes. The main advantage of NIR light is that it can penetrate tissue in the order of centimeters, allowing the surgeon to visualize tumors underneath the tissue surface that can be detected using a dedicated imaging system."

Related Links:
Purdue University
Centre for Human Drug Research
Leiden University Medical Center
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Portable Radiology System
DRAGON ELITE & CLASSIC
MRI System
uMR 588
New
Ultrasound Needle Guide
Ultra-Pro II

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.